11th week of 2009 patent applcation highlights part 39 |
Patent application number | Title | Published |
20090068189 | Monoclonal Antibody to Human TGF-Beta Induced Gene-H3 and Use Thereof - The present invention relates to a monoclonal antibody to human βig-h3 and the use thereof. More particularly, it relates to a monoclonal antibody to the human βig-h3 protein, wherein the epitope of the monoclonal antibody is the H1 region of the fourth fas-1 domain of the human βig-h3 protein. The monoclonal antibody can specifically recognize the human βig-h3 protein in tissue, and so will be useful in diagnosing a disease associated with the increase or decrease of the βig-h3 protein. In addition, the monoclonal antibody has the effect of inhibiting the cell adhesion activity of the βig-h3 protein. | 2009-03-12 |
20090068190 | ANTI-PROLIFERATIVE COMBINATIONS - Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane. | 2009-03-12 |
20090068191 | Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of the Pseudomonas Aeruginosa IATS 011 Serotype - The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of | 2009-03-12 |
20090068192 | Fully human antibodies against human 4-1BB - Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject. | 2009-03-12 |
20090068193 | Treatment And Prophylaxis With 4-1BB-Binding Agents - Materials and Methods for using 4-1BB agonists to treat or prevent autoimmune disorders, lymphoproliferative diseases, and allergies are provided. | 2009-03-12 |
20090068194 | Antibodies and Their Use In The Treatment, Prevention and Diagnosis of a Disease Associated With SOD1 Abnormalities - The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADI-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human. | 2009-03-12 |
20090068195 | METHODS AND COMPOSITIONS FOR TREATING AND MONITORING TREATMENT OF IL-13-ASSOCIATED DISORDERS - Methods and compositions for reducing or inhibiting, or preventing or delaying the onset of, one or more symptoms associated with an early and/or a late phase of an IL-13-associated disorder or condition using IL-13 binding agents are disclosed. Methods for evaluating the kinetics and/or efficacy of an IL-13 binding agent in treating or preventing an IL-13-associated disorder or condition in a subject, e.g., a human subject, are also disclosed. | 2009-03-12 |
20090068196 | Pharmaceutical formulation of an antibody against IL13Ralpha1 - Pharmaceutical formulations of an antibody against IL13Rα | 2009-03-12 |
20090068197 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY - Methods for detecting and treating | 2009-03-12 |
20090068198 | Antibody and Uses Thereof - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis. | 2009-03-12 |
20090068199 | Methods for Treating and Detecting Beta-Cell Disease - The role of synaptic adhesion molecules in human cell development and function is largely unknown. This invention provides methods to study β-cell function in native tissue through the use of novel adhesion and migrations assays. Through the use of these assays, the inventors have been able to for the first time describe the contribution of SAMs to human β-cell adhesion, spreading, and motility. Furthermore, the inventors have used the results of these assays to develop methods for detection, treatment, and prevention of diseases related to the pancreas. | 2009-03-12 |
20090068200 | Method for Prongf Assay for in Vitro Diagnosis of Cancer in Particular Breast, Thyroid or Lung Cancer, and Therapeutic Use of Prongf - The present invention concerns a method for in vitro diagnosis of cancer, in particular breast, thyroid or lung cancer, which consists in determining the presence of ProNGF in a biological sample derived from a patient suspected of suffering from cancer, in particular breast, thyroid or lung cancer. Said method may be used for early diagnosis, screening, therapeutic follow-up, prognosis and for diagnosing relapses in cancer and in particular breast, thyroid or lung cancer. | 2009-03-12 |
20090068201 | METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA - The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders. | 2009-03-12 |
20090068202 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2009-03-12 |
20090068203 | Methods for treating cardiovascular disease using a soluble CTLA4 Molecule - The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands. | 2009-03-12 |
20090068204 | Morinda citrifolia Based Formulations for Regulating T cell Immunomodulation in Neonatal Stock Animals - Both liquid and dry form | 2009-03-12 |
20090068205 | ErbB4 antagonists - The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells. | 2009-03-12 |
20090068206 | Delivery of pharmaceutical agents via the human insulin receptor - A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human organs and tissue that express the HIR. The humanized murine antibody is especially well suited for delivering neuropharmaceutical agents from the blood stream to the brain across the blood brain barrier (BBB). The humanized murine antibody may be genetically fused to the pharmaceutical agent or it may be linked to the pharmaceutical agent using an avidin-biotin conjugation system. | 2009-03-12 |
20090068207 | Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease - Methods and compositions employing beta | 2009-03-12 |
20090068208 | LONG TERM DISEASE MODIFICATION USING IMMUNOSTIMULATORY OLIGONUCLEOTIDES - The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification. | 2009-03-12 |
20090068209 | Cytotoxic Lymphocyte - The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte. | 2009-03-12 |
20090068210 | IMMUNOTHERAPY FOR HEMATOLOGICAL MALIGNANCIES - Methods and compositions for treating, preventing and/or managing various hematological malignancies are disclosed. Specific methods and compositions relate to use of tumor cells engineered to express antigen presenting molecules which present antigens recognized by iNKT cells and eliciting antitumor immune response from iNKT cells using such tumor cells, optionally in combination with an immunomodulatory compound. | 2009-03-12 |
20090068211 | IMMUNOGENICALLY-ENHANCED POLYPEPTIDES AND RELATED METHODS - Described herein are immunogenically-enhanced polypeptides, such as KSHV LANA1 polypeptides, related methods of eliciting an immune response to the polypeptides and related nucleotide sequences. Also described herein are novel polypeptides capable of inhibiting degradation and/or retarding synthesis of a protein when attached to or incorporated within that protein along with related methods and nucleotide sequences. | 2009-03-12 |
20090068212 | Proteins derived from white spot syndrome virus and uses thereof - Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans. | 2009-03-12 |
20090068213 | Early detection of flaviviruses using the NS1 glycoprotein - The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least two identical or different antibodies, the first antibody consisting of polyclonal or monoclonal antibodies pre-selected for their high affinity for said NS1 protein hexameric in shape. | 2009-03-12 |
20090068214 | Methods and Compositions for Producing an Enhanced Immune Response to a Human Papillomavirus Immunogen - The present invention relates to novel methods for producing an enhanced immune response to an immunogen in a subject via the co-administration of a CD40 agonist and a GM-CSF agent. | 2009-03-12 |
20090068215 | HERPES SIMPLEX VIRUS MUTANT ICP0 PROTEIN - A mutant virus of herpes simplex virus type 1 (HSV-1) can include a mutant protein involved in replication so as to impair or inhibit replication of HSV-1. The mutant HSV-1 can have a mutation in at least one phosphorylation site of a protein involved in replication in order to inhibit phosphorylation of the site so as to prohibit or impair replication of HSV-1 and/or the clinical severity of HSV-1-mediated diseases. The mutant protein can be a mutant ICP0 that has reduced or inhibited posttranslational phosphorylation. The mutant HSV-1 and/or mutant ICP0 can be used in vaccines or other pharmaceutical preparations to treat, limit and/or prevent HSV-1 infection. The mutant HSV-1 and/or mutant ICP0 can also be used in screening and/or developing anti-HSV-1 agents. | 2009-03-12 |
20090068216 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 2009-03-12 |
20090068217 | Recombinant vaccine for preventing and treating porcine atrophic rhinitis - Disclosed is a recombinant vaccine for porcine atrophic rhinitis. A vaccine is provided which uses a | 2009-03-12 |
20090068218 | Antigens for Vaccination Against and Detection of Mycoplasma Suis - The present invention relates to antigens for vaccination against and detection of | 2009-03-12 |
20090068219 | Anti-wrinkle hormone-type cosmetic composition - A cosmetic anti-aging composition comprising an effective amount of Human Oligopeptide-9 in combination with at least one additional oligopeptide is provided. The composition displays a very surprisingly and highly beneficial synergistic effect for treatment of fine line and wrinkles, skin brightening, skin re-texturization, and/or thickening of the skin, etc. | 2009-03-12 |
20090068221 | Virus-like particles as vaccines for paramyxovirus - The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines. | 2009-03-12 |
20090068222 | METHODS TO INCREASE TRANSGENE EXPRESSION FROM BACTERIAL-BASED DELIVERY SYSTEMS BY CO-EXPRESSING SUPPRESSORS OF THE EUKARYOTIC TYPE I INTERFERON RESPONSE - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene. | 2009-03-12 |
20090068223 | COMBINATION VACCINE COMPRISING AN ATTENUATED BOVINE VIRAL DIARRHEA VIRUS - The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections, and a further immunological active component for the prophylaxis and treatment of microbiological infections other than BVDV. | 2009-03-12 |
20090068224 | METHOD TO IDENTIFY POLYPEPTIDE TOLL-LIKE RECEPTOR (TLR) LIGANDS - The present invention provides novel methods to identify polypeptide ligands for Toll-like Receptors (TLRs), such as TLR2, TLR4 and TLR5. The method involves the use of phage display technology in an iterative biopanning procedure. The invention also provides polypeptide TLR ligands identified by the methods of the invention. In preferred embodiments, the polypeptide TLR ligands so identified modulate TLR signaling and thereby regulate the Innate Immune Response. The invention also provides vaccines comprising a polypeptide TLR ligand identified by the methods of the invention and an antigen. The invention also provides methods of modulating TLR signaling using the polypeptide TLR ligands and vaccines of the invention. | 2009-03-12 |
20090068225 | COMPOSITIONS AND METHODS FOR ORTHOPOX VIRUS VACCINATION - The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to an orthopox virus (e.g., vaccinia virus) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising vaccinia virus). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination) and research applications. | 2009-03-12 |
20090068226 | Bacterial superantigen vaccines - The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described. | 2009-03-12 |
20090068227 | Use of neurotoxin therapy for treatment of urologic and related disorders - The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | 2009-03-12 |
20090068228 | METHOD OF SEPARATING PROTECTIVE COMPONENTS OF BORDETELLA PERTUSSIS - To provide a method of efficiently separate protective components of | 2009-03-12 |
20090068229 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 2009-03-12 |
20090068230 | ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE - Compositions and methods for stimulating an immune response against a secreted enterohemorragic | 2009-03-12 |
20090068231 | LIVE ATTENUATED MYCOPLASMA STRAINS - The present invention provides live, attenuated | 2009-03-12 |
20090068232 | ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS - The present invention provides live, attenuated | 2009-03-12 |
20090068233 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND IMMUNOTHERAPY OF POLLEN ALLERGY - A diagnostic pollen array includes allergens extracted from pollen coat material. Diagnostic pollen arrays are useful to diagnose allergy in individuals, identify novel allergens, identify genetic loci responsible for allergy in hosts, and to develop treatment plans for allergy. | 2009-03-12 |
20090068234 | Methods and compositions for the treatment and prevention of cancer - The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3α/CCL20 or β-defensin mDF2β. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer. | 2009-03-12 |
20090068235 | IMMUNOGENIC CD19 PEPTIDES - The invention provides relatively short immunogenic peptides derived from CD19 antigens, and biologically active variants thereof, which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and used for the treatment of cancer. | 2009-03-12 |
20090068236 | Oral Cephalotaxine Dosage Forms - The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations. | 2009-03-12 |
20090068237 | Dry eye treatment - This invention relates to an emulsion composition for the formation of an artificial tear film over the ocular surface of the eye capable of providing mechanical lubrication for the ocular surface while reducing evaporation of fluid therefrom. The emulsion is desirably in the form of a meta stable emulsion and is characterized by the use of a surfactant comprising a combination of a primary and secondary surfactant where the primary surfactant permits formation of the emulsion and the secondary surfactant permits autoclaving of the surfactant. The invention also includes a method for the formation of such an emulsion. | 2009-03-12 |
20090068238 | Cosmetic composition containing elastomers - The present invention relates to a solid anhydrous cosmetic composition comprising at least one non-spherical silicone elastomer and at least one silicone elastomer powder coated with a silicone resin. The invention also relates to a makeup process comprising the application to keratin materials of the said composition, and also to its use for obtaining a uniform makeup result that shows good fastness of the color over time. | 2009-03-12 |
20090068239 | REFRESHMENT TOWEL AND APPLIED SOLUTION - A refreshment towel with applied solution is an apparatus consisting of a carrying agent, most likely a high quality cotton towel or towelette, that has been saturated with an aqueous solution comprised of various ingredients. The resulting saturated towel can be rubbed on a user's skin such that the aqueous solution that has been absorbed by the towel is transferred. The aqueous solution is compounded specifically to provide cooling, insect repellant, sun protection, freshness, cleansing and other uses. More specifically, the aqueous solution is specially formulated so that desired sensory results take place when the towel comes in contact with the skin. | 2009-03-12 |
20090068240 | COSMETIC TOOL - A cosmetic tool characterized in that: its structure is such that the first sheet to fourth sheet are stitched up along their peripheries, with the stitched part prevented from projecting outward along the entire periphery; a powder cosmetic material is filled between the second sheet and third sheet allowing powder to pass through; a foamed sheet having through holes is placed between the first sheet and second sheet and/or between the third sheet and fourth sheet; and the passing amount of aforementioned powder cosmetic material is different on the first sheet side and fourth sheet side; and therefore the transuding amount of powder cosmetic material varies and thereby excellent efficiency is achieved when used for cosmetic purposes. | 2009-03-12 |
20090068241 | DEPOSITION OF METALS ONTO NANOTUBE TRANSPARENT CONDUCTORS - This invention is directed to compositions and methods of incorporating metal particles into carbon nanotube films, sheets, and networks. Metal salts that are soluble in water, alcohol, polar organic solvents, and mixtures thereof are used to deposit metal particles onto carbon nanotube films, sheets, and networks. Metal salts increase conductance of nanotube films by spontaneously depositing gold on the nanotube. The concentration and time of exposure to metal salt solution allows the tuning of conductivity and transparency for a transparent carbon nanotube network. Metal salts added to nanotube ink add functional properties of the metal to nanotube conductors. | 2009-03-12 |
20090068242 | INSECTICIDAL CARBAMATES EXHIBITING SPECIES-SELECTIVE INHIBITION OF ACETYLCHOLINESTERASE (AChE) - The present invention includes insecticidal carbamates that are useful, for example, for the control of insects, such as mosquitoes, which can be used in applications where exposure to and/or contact with humans is likely. The insecticides of the present invention include phenyl N-methyl carbamates and compositions comprising them that exhibit species-selective inhibition of acetylcholinesterase (AChE) and are preferably toxic to mosquitoes but not humans. Of particular interest are compounds of Formula (I) and Formula (II): | 2009-03-12 |
20090068243 | Novel formulations for delivery of antiviral peptide therapeutics - Provided herein are compositions and methods for their administration as therapeutic agents. In particular, provided herein are compositions and their use for the administration of antiviral peptide therapeutics. | 2009-03-12 |
20090068244 | Polymeric/carbon composite materials for use in medical devices - The invention provides implantable or insertable medical devices, which contain one or more composite regions. These composite regions, in turn, contain polymer and carbon particles. Also, the invention provides composite materials for use in a medical device containing styrene-isobutylene copolymer and carbon nanotubes. | 2009-03-12 |
20090068245 | Porous Laser Sintered Articles - The present invention provides selectively laser sintered porous polymeric articles and methods of making and using the same. In one embodiment, a method of the present invention comprises providing a first layer of particles of a first polymeric material, heating selected locations of the first layer to sinter particles of the first polymeric material to form a three-dimensional article, the three-dimensional article having a porosity of at least about 30 percent. | 2009-03-12 |
20090068246 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF - The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof. | 2009-03-12 |
20090068247 | BIOCOMPATIBLE DEVICES COATED WITH A TRIBONECTIN AND METHODS FOR THEIR PRODUCTION - The present invention features biocompatible devices having a surface thereof coated with a composition that includes a tribonectin, and methods of making the devices. The tribonectin may, e.g., reduce microbial growth on or attachment to the surface of the biocompatible device. | 2009-03-12 |
20090068248 | POLYDIAZENIUMDIOLATED CYCLIC POLYAMINES WITH POLYPHASIC NITRIC OXIDE RELEASE AND RELATED COMPOUNDS, COMPOSITIONS COMPRISING SAME AND METHODS OF USING SAME - The present invention provides compound of the formula (I): | 2009-03-12 |
20090068249 | METAL ALLOYS FOR MEDICAL DEVICES - A medical device that is at least partially formed of a novel metal alloy, which novel metal alloy improves the physical properties of the medical device. | 2009-03-12 |
20090068250 | Bioresorbable and biocompatible compounds for surgical use - A bioresorbable and biocompatible compound for surgical use is composed of functionalized collagen cross-linked with a glycosaminoglycan. | 2009-03-12 |
20090068251 | METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING - Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds. | 2009-03-12 |
20090068252 | Transdermal Absorption Preparation - A transdermal absorption preparation having a support and a pressure-sensitive adhesive layer consisting of multiple layers, wherein the pressure-sensitive adhesive layer comprises a drug-retaining layer containing a drug and an acrylic pressure-sensitive adhesive and a skin adhesion layer containing a styrene-isoprene-styrene block copolymer. This preparation can continuously release bisoprolol at a constant concentration. Moreover, it can be easily produced. | 2009-03-12 |
20090068253 | METHOD FOR THE TREATMENT OF INFECTION WITH HHV-6 VIRUS AND THE AMELIORATION OF SYMPTOMS RELATED TO VIRUS USING LIPOSOMAL ENCAPSULATION FOR DELIVERY OF REDUCED GLUTATHIONE - The invention is the use of a therapeutically effective amount of glutathione (reduced) in a liposome encapsulation for oral administration to improve symptoms of illnesses that are related to viruses and for the treatment and prevention of virus, particularly HHV-6 and EBV, which liposomal encapsulation of glutathione (reduced) is referred to as liposomal glutathione. The application references specifically reduced glutathione and its importance, and how to stabilize it effectively so it can be taken orally, and need not be refrigerated. New uses for tuberculosis, and asthma are discussed. The combination is proposed of reduced glutathione and Highly Active Anti-Retroviral Therapy having at least one pharmaceutical composition selected from the group of Nucleoside/tide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), and Non-nucleoside Reverse Transcriptase Inhibitors (NnRTIs). | 2009-03-12 |
20090068254 | MULTIVALENT LIPOSOMAL VACCINE COMPOSITIONS COMPRISING POLYSACCHARIDE ANTIGENS AND A PROTEIN ADJUVANT - A multivalent liposomal composition, preferably a vaccine, comprises liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigens of several serotypes and T-cell dependent protein carrier, such as tetanus toxoid. The invention is of use in the production of vaccines against | 2009-03-12 |
20090068255 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE - The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cosmetically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease). | 2009-03-12 |
20090068256 | Encapsulation of Bioactive Complexes in Liposomes - This invention provides a method to prepare liposome-encapsulated bioactive agents, such as nucleic acids, comprising complexation of the bioactive agents to reverse micelles prior to forming liposomes, as well as methods of using the liposomes so formed and formulations to deliver nucleic acids to cells. | 2009-03-12 |
20090068257 | BETULONIC AND BETULINIC ACID DERIVATIVES - The present invention relates to betulonic and betulinic acid derivatives and, in particular, to C-28 and C-3 derivatives. The present invention relates to betulonic acid esters, dihydro-betulonic acid esters, PAG-modified betulinic acid derivatives, and PAG-modified dihydro-betulinic acid derivatives. Betulinic acid and derivatives thereof may be bound to a poly(alkylene glycol) (PAG) such as poly(ethylene glycol). Binding may be via a linker, such as a diamine, an amino acid, a peptide, an ester or a carbonate. | 2009-03-12 |
20090068258 | Caveolin-mimetic peptide for prevention and treatment of pulmonary hypertension and right ventricular hypertrophy - Methods are provided for preventing and treating pulmonary hypertension and right ventricular hypertrophy involving administering to a patient a caveolin peptide coupled to a cell permeating compound such as a cell permeating peptide. | 2009-03-12 |
20090068259 | Controlled Surface Gelling of Mucoadhesive Polymers on Oral Mucosa - The present invention relates to an oral composition and method for alleviating the symptoms associated with xerostomia using encapsulated cation-releasing compounds formulated either intimately together or in separate compartments in a composition containing cation-sensitive mucoadhesive polymers. | 2009-03-12 |
20090068260 | BETA-1-SELECTIVE ADRENOCEPTOR BLOCKING AGENT COMPOSITIONS AND METHODS FOR THEIR PREPARATION - The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient, optionally also comprising a diuretic such as but not limited to hydrochlorothiazide, and methods of preparing such extended release pharmaceutical compositions. | 2009-03-12 |
20090068261 | ORAL RAPID RELEASE PHARMACEUTICAL FORMULATION FOR PYRIDYLMETHYLSULFINYL-BENZIMIDAZOLES - The invention relates to solid oral pharmaceutical compositions in the form of pellets, mini-tablets, tablets, or capsules, comprising an optionally substituted 2-(pyridylmethylsulfinyl)-1H-benzimidazole, for example esomeprazole, and carrageenan, and optionally one or more excipients. Surprisingly, it has been found that these compositions are stable and rapidly release the active ingredient. The pellets or mini-tablets may be coated as such, or filled in capsules or pressed into tablets, with a polymer, which dissolves only at a pH value of 5 or higher, optionally over a stabilizing intermediate layer. | 2009-03-12 |
20090068262 | Rapid dissolution of combination products - Provided are rapidly dissolving pharmaceutical oral dosage forms of triptans and NSAIDs, processes for the preparation thereof, and methods of treatment therewith. | 2009-03-12 |
20090068263 | MULTIPLE UNIT COMPOSITIONS - The present invention provides a multiple unit compositions comprising of enteric coated pellets and at least one tablet excipient, wherein each pellet comprises: i) a core comprising active ingredient(s); ii) optionally a separating layer coated on the core; iii) at least two enteric layers comprising of enteric polymers and plasticizer either coated on the core or on the separating layer to obtain enteric coated pellets, such that the last enteric layer is formed from a solution comprising of enteric polymer and plasticizer in organic solvent(s), resulting in no appreciable change in release profile of active ingredient on compression of enteric coated pellets into tablets. | 2009-03-12 |
20090068264 | Clinical Applications of Tetrahydrobiopterin, Lipoic Acid and Their Salts and Methods of Preparing Tetrahydrobiopterin Bis-Lipoate - Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease, hearing loss and chronic glaucomas). A novel method for the preparation of TBL is also disclosed. | 2009-03-12 |
20090068265 | ECKLONIA CAVA EXTRACTS FOR ALLEVIATING OR PREVENTING ASTHMATIC REACTIONS - A method of alleviating or preventing inflammation in an animal is provided. In concrete, the method comprises the step of administering to an animal a composition including an Ecklonia cava extract in an amount effective to suppress SOCS-3 expression in the animal to thereby alleviate or prevent inflammation in the animal. | 2009-03-12 |
20090068266 | SIROLIMUS HAVING SPECIFIC PARTICLE SIZE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Sirolimus particles having d | 2009-03-12 |
20090068267 | Novel Pharmaceutical Compositions - The present invention relates to novel lamivudine/cyclodextrin complexes and processes for preparing said complexes. The present invention also relates to novel solid pharmaceutical compositions comprising lamivudine, wherein lamivudine is present in the form of said lamivudine/cyclodextrin complexes. The present invention further relates to processes for preparing said compositions. | 2009-03-12 |
20090068268 | MELT GRANULATION OF A COMPOSITION CONTAINING A CALCIUM-CONTAINING COMPOUND - A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is substantially achieved and an unpleasant mouth feel of the calcium-containing compound is substantially avoided, while at the same time obtaining a low tablet volume. The method of the invention is especially suitable for the manufacturing of tablets having a high load of a calcium-containing compound. | 2009-03-12 |
20090068270 | Treatment of degenerated disc with autologous cells - The present invention relates to administering autologous uncultured cells into a diseased intervertebral disc. | 2009-03-12 |
20090068271 | EMBOLIZATION PARTICLES - Embolic particles, embolic particle chains, and methods for making embolic particles and embolic particle chains are described. | 2009-03-12 |
20090068272 | MESOPOROUS CALCIUM SILICATE COMPOSITIONS AND METHODS FOR SYNTHESIS OF MESOPOROUS CALCIUM SILICATE FOR CONTROLLED RELEASE OF BIOACTIVE AGENTS - Mesoporous calcium silicate compositions for controlled release of bioactive agents and methods for producing such compositions are disclosed herein. In one embodiment, mesoporous calcium silicate is synthesized by acid modification of wollastonite particles using hydrochloric acid. A hydrated silica gel layer having abundant Si—OH functional groups can be formed on the surface of wollastonite after acid modification. Bruhauer-Emmett-Teller (BET) surface area increased significantly due to acid modification and, in one arrangement, reached over 350 m | 2009-03-12 |
20090068273 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases - The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices | 2009-03-12 |
20090068274 | HIGHLY EFFICIENT DELIVERY OF A LARGE THERAPEUTIC MASS AEROSOL - A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm | 2009-03-12 |
20090068275 | Process for the Manufacture of Powders of Inhalable Medicaments - The invention relates to an improved process for the production of powders of an inhalable medicament by crystallization from a supersaturated fluid containing said medicament, the method comprising passing along a tubular reactor
| 2009-03-12 |
20090068276 | Pharmaceutical compositions - The present invention relates to new pharmaceutical formulations comprising pharmaceutically active agents which can induce one or more involuntary coughs in a patient when administered as conventional formulations and/or via conventional routes. Formulations are provided comprising a cough-inducing pharmaceutically active agent, wherein the formulation may be administered by pulmonary inhalation without inducing a cough. Alternatively, formulations are provided for administering the cough-inducing active agent via an alternative route. | 2009-03-12 |
20090068277 | PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR AND LIPOPHILIC OIL ABSORBENT AND ORAL FORMULATION PREPARED THEREFROM - This invention provides a pharmaceutical composition comprising a lipase inhibitor; a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and a method for preparing said formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty/oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipaemia. | 2009-03-12 |
20090068278 | USE OF FREE RADICAL SCAVENGERS FOR PROTECTING AND TREATING SKIN AND HAIR DAMAGES CAUSED BY CHEMOTHERAPY - The present invention relates to the use of one or more free radical scavengers as prophylactically or therapeutically effective substances and microparticles having an average particle size ranging from 5 to 200 μm for the preparation of a topical pharmaceutical composition for the protection or treatment of skin or hair damages caused by chemotherapeutic treatment. | 2009-03-12 |
20090068279 | MICROSPHERES WITH SURFACE PROJECTIONS - Methods of making polymer particles, as well as related particles, compositions, and methods are disclosed. | 2009-03-12 |
20090068280 | Controlled Release Interferon Drug Products and Treatment of HCV Infections Using Same - The invention relates to controlled release formulations comprising a microparticle comprising a biodegradable polymer and one or more interferon compounds and methods of using the formulations. | 2009-03-12 |
20090068281 | Composition, Functional Food and Pharmaceutical Composition for Improvement in Obesity - A composition for improving obesity is disclosed. The composition contains a natural ingredient free of side effects in daily intake as an active ingredient. The composition is capable of remarkably reducing body fat, as compared with a conventional ingredient which is derived from a natural ingredient as an active ingredient, and is capable of suppressing fat storage. The composition includes a meat extract or a fish meat extract, and a fat storage suppressive substance. | 2009-03-12 |
20090068282 | Use of metal complex compounds as oxidation catalysts - Use of metal complex compounds of formula | 2009-03-12 |
20090068283 | Silver-based inorganic antimicrobial agent and antimicrobial product - The present invention is to provide a silver-based inorganic antimicrobial agent that has excellent heat resistance and chemical resistance, that gives little resin coloration, and that has excellent processability. | 2009-03-12 |
20090068284 | Method for treating menorrhagia - A delivery vehicle for a silver ion source such as silver nitrate and the like, suitable for use in the treatment of menorrhagia, comprises a plurality of physiologically inert beads bearing a tissue cauterizing amount of a silver ion source. Preferably the beads are made of a physiologically inert polymer, ceramic or stainless steel. The silver ion source preferably is silver nitrate and can be substantially pure silver nitrate, or can comprise silver nitrate in combination with a physiologically tolerable binder or a diluent. Suitable binders include physiologically tolerable synthetic polymeric binders, polysaccharide binders, and the like. Diluents can include other salt materials such as potassium nitrate. The beads are useful in treating menorrhagia of a mammalian uterus. The beads can be delivered to the uterus via a catheter, and are distributed throughout the uterine cavity by uterine massage or like expedient. Silver ions are delivered to the endometrium and cause necrosis of the endometrial tissue. The silver ions remaining within the uterine cavity can then be neutralized with a sodium chloride solution delivered to the uterus e.g., by catheter, and the beads recovered from the uterus. | 2009-03-12 |
20090068285 | Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate - The present invention provides novel biomaterials comprising one or more of Mg, Zn and F ions in a carbonate-containing biphasic calcium phosphate (BCP) system. The biomaterial may contain Mg, Zn, F, Mg and Zn, Mg and F, Zn and F, or Mg, Zn and F. The biomaterial may be substantially similar in composition to bone mineral (a carbonate apatite). The biomaterial may feature slow release of Mg, Zn, F, Ca, and P ions. The biphasic calcium phosphate, BCP, may be a mixture of unsubstituted hydroxyapatite (HA) and unsubstituted .-TCP, Ca | 2009-03-12 |
20090068286 | METHOD OF TREATING CANCER BY ADMINISTRATION OF 5-SUBSTITUTED NUCLEOSIDES - The invention relates to methods of administration of at least one overexpression inhibitor of DNA repair genes and/or oncogenes (e.g., (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU), or a prodrug, or salt thereof) to increase the cytotoxic effect of a cytostatic or cytotoxic chemotherapeutic agent during and/or after chemotherapy, e.g., in the treatment of cancer. | 2009-03-12 |
20090068287 | Novel topical formulations of flucytosine and uses thereof - The invention relates to topical formulations and methods of use of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of | 2009-03-12 |
20090068288 | Topical antiseptic veterinary solution - This invention relates to a veterinary antiseptic solution having three sources of iodine including elemental iodine, iodide salt and iodophor. The solution also includes at least one solvent such as alcohol, glycol or water. The solution is below the threshold concentration for elemental iodine of the List I controlled substances. The elemental iodine offers a rapid kill for bacteria. The iodophor offers lasting antibacterial properties. The iodide salt solubilizes elemental iodine and stabilizes the solution. The antiseptic solution forms a waterproof bandage with active antimicrobial properties when the alcohol dries. | 2009-03-12 |
20090068289 | FORMULATION FOR MENOPAUSAL WOMEN - The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from systems associated with menopause, as well as prophylactic effects, and methods for using same. | 2009-03-12 |
20090068290 | BIFEPRUNOX DOSES FOR TREATING SCHIZOPHRENIA - The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic. | 2009-03-12 |